Autologous Cell Therapy with CD133+ Bone Marrow-Derived Stem Cells for Asherman Syndrome: A Phase I/II Trial

This phase I/II, non-randomized, open-label, single-arm trial assessed the safety and efficacy of this novel therapy in 20 infertile women with moderate to severe Asherman Syndrome, unresponsive to prior hysteroscopic treatments.